Chimerix, Inc. (NASDAQ:CMRX) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Wednesday.
Separately, Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Wednesday, August 9th.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.05. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%. The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $1.28 million.
ILLEGAL ACTIVITY NOTICE: “ValuEngine Upgrades Chimerix, Inc. (CMRX) to “Sell”” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.com-unik.info/2017/10/13/valuengine-upgrades-chimerix-inc-cmrx-to-sell.html.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
What are top analysts saying about Chimerix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chimerix Inc. and related companies.